key: cord-0015120-o1rcs21p
authors: Houston, Hamish; Gupta-Wright, Ankur; Toke-Bjolgerud, Edward; Biggin-Lamming, James; John, Laurence
title: Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19
date: 2021-02-01
journal: J Hosp Infect
DOI: 10.1016/j.jhin.2021.01.018
sha: 7a39e3b3c341720c0be9471960d04f2b848cf1ad
doc_id: 15120
cord_uid: o1rcs21p

nan

Dear Editor,

The scale-up of SARS-CoV-2 antigen lateral flow assays (LFAs) has caused much controversy, with concerns about lower sensitivity in asymptomatic individuals and when assays are performed by operators without healthcare training. 1, 2 The proposed benefits of SARS-CoV-2 antigen LFAs are high specificity, fast turnaround times for results (under 30 minutes) and ease of scalability. 3 These assays are of potential utility for rapidly identifying SARS-CoV-2 in patients who fit the COVID-19 case definition and require hospital admission as prompt isolation prevents nosocomial transmission.

Isolation rooms are often limited and capacity easily overwhelmed, necessitating the cohorting of patients with proven COVID-19. Even using rapid platforms, SARS-CoV-2 RT-PCR turnaround times are often too slow to inform patient placement from emergency departments (EDs). 4 

LFAs could help improve flow of patients from the ED into 'COVID-19 positive' cohorts and reduce pressure on limited hospital isolation rooms. However, little data exists on their diagnostic accuracy in this setting.

We therefore evaluated diagnostic accuracy of the Innova SARS-CoV-2 Antigen Rapid Qualitative Test (Lotus Global Company, London, UK) compared to SARS-CoV-2 RT-PCR from nasopharyngeal swabs (NPS) in adult admissions who met the COVID-19 case definition at a busy acute hospital in the UK. 5 The Innova LFA was performed as per the manufacturer's instructions by appropriately trained health-care assistants in the ED. A second NPS was simultaneously sent for SARS-CoV-2 RT-PCR. Between the 17 th November 2020 and 31 st December 2020, 728 patients presenting to the ED met the COVID-19 case definition and had valid Innova LFA and RT-PCR results. Baseline characteristics are shown in Table 1A . 55·1% were male and median age was 67·5 years. 264 patients tested positive by Innova LFA. Those testing positive were younger (median age 65 vs 71, p=0.038), more unwell (NEWS of 5 vs 3, p<0.001) and more often febrile on arrival (Temperature >38°C in J o u r n a l P r e -p r o o f 41·9% vs 15·8%, p<0.001) than those with negative LFA results. Overall, admission SARS-CoV-2 RT-PCR was positive in 38·5% (280/728).

Compared to SARS-CoV-2 RT-PCR as the reference standard, the Innova LFA had sensitivity of 86·4% (242/280, 95% Confidence Interval [CI] 81·9-90·0) and specificity of 95·1% (426/448, 95%CI 92·6-96·7) (Table 1B) Accounting for the inadequacy of a single SARS-CoV-2 RT-PCR as a reference standard, we found the Innova SARS-CoV-2 Antigen Rapid Qualitative Test had good specificity in patients with symptoms of COVID-19 presenting to hospital. Sensitivity in this setting was high (86.4%) when compared to preclinical evaluation studies. 1 Furthermore, results were mostly available within a few hours of J o u r n a l P r e -p r o o f presentation, allowing transfer of patients to COVID-19 cohort areas and reducing demand for isolation rooms whilst awaiting PCR results. Placing patients in the 'right bed' first-time is also likely to reduce delays in care and increase efficiency, and allows isolation rooms to be prioritised for individuals requiring admission with suspected COVID-19 but negative LFA results. Of the 38 patients with COVID-19 (based on SARS-CoV-2 RT-PCR) who were 'missed' by the Innova LFA, median Ct values were reasonably high, and correspond to viral loads associated with lower sensitivity in previous studies. 1 However, sensitivity of the Innova LFA appears lower than some other SARS-CoV-2 viral antigen LFAs . 7 Importantly, individuals requiring admission with suspected COVID-19 should not be moved out of isolation on the basis of a negative SARS-CoV-2 viral antigen LFA results.

In summary, the Innova LFA can be used to rapidly identify COVID-19 cases amongst hospital admissions meeting the COVID-19 case definition with good diagnostic accuracy, and rapidly identify patients that can be allocated to COVID-19 cohort areas. Based on these data, this application of COVID-19 LFAs has now been recommended by NHS England. 8

Funding: This study received no specific grant from any funding agency in the public, commercial or not-for-profit sector. The manufacturer (Lotus Global Company, London, UK) had no role in the study conception, design, data analysis or manuscript preparation.

Approval: The study was approved by the London North West University Hospitals Trust Research and Development Committee, and given the SARS-CoV-2 antigen lateral flow assay was implemented as part of routine clinical care and this was a retrospective review using routinely collected clinical data, they deemed formal ethical approval was not required. 

Preliminary report from the Joint PHE Porton Down & University of Oxford SARS-CoV-2 test development and validation cell: Rapid evaluation of Lateral Flow Viral Antigen detection devices (LFDs) for mass community testing

Operation Moonshot proposals are scientifically unsound

World Health Organization. SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide

Clinical impact of molecular point-of-care testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study

World Health Organization. WHO COVID-19 case definition

False Negative Tests for SARS-CoV-2 Infection -Challenges and Implications

Field performance and public health response using the BinaxNOW TM Rapid SARS-CoV-2 antigen detection assay during community-based testing

Novel coronavirus (COVID-19) standard operating procedure: lateral flow device testing for emergency department patient pathways

Age on arrival (years) median (IQR) 71 (53·5, 83) (n=464) 65 (49·5, 80) (n=264) 67·5

Age over 65 years, n (%, 95%CI) 260 (56·0%, 51·5 -60·6) 125 (47·3%, 41·3 -53·4) 385 (52·9%

Female Sex, n (%) 211 (45·5%, 40·9 -50·0) 116 (43·9%, 38·0 -49·9) 327 (44·9%, 41·3 -48·5) 0·69

Male Sex, n (%) 253 (54·5%, 50·0 -59·1) 148 (56·1%, 50·1 -62·0) 401 (55·1%

Respiratory rate, median (IQR) 20

SpO2 <94%, n (%, 95%CI) 55 (12·9%, 9·8 -16·1) 68 (29·7%, 23·8 -35·6) 123 (18·8%

Temperature >38°C, n (%, 95%CI) 67 (15·8%, 12·3 -19·2) 96 (41·9%, 35·5 -48·3) 163 (24·9%

Acknowledgements: We would like to acknowledge to all the clinical staff at Northwick Park Hospital who cared for the patients involved in this study, particularly the point-of-care team within the emergency department.Conflicts of interest: The authors declare that they have no competing interests.J o u r n a l P r e -p r o o f